Mitochondrial transplantation is an emerging therapeutic approach that introduces healthy, functional mitochondria into damaged cells to restore cellular energy metabolism. Transplanted mitochondria can restore ATP production, reduce reactive oxygen species (ROS), attenuate apoptosis, and facilitate neural repair. This approach addresses a central pathogenic mechanism shared across neurodegenerative diseases: mitochondrial dysfunction characterized by impaired oxidative phosphorylation, increased ROS generation, defective mitophagy, and progressive energy crisis leading to neuronal death.
- Energy restoration: Exogenous mitochondria integrate into recipient cells and resume oxidative phosphorylation, restoring ATP production
- ROS reduction: Functional mitochondria have intact electron transport chains with minimal electron leak, reducing oxidative stress
- Anti-apoptotic signaling: Healthy mitochondria maintain membrane potential and suppress cytochrome c release, reducing caspase activation
- Mitophagy normalization: Transplanted mitochondria may help restore quality control pathways (PINK1/Parkin) disrupted in disease
- Calcium buffering: Functional mitochondria restore ER-mitochondria calcium homeostasis
Cells naturally transfer mitochondria via several mechanisms:
- Tunneling nanotubes (TNTs): F-actin based membrane channels (50-300 μm long, 50-200 nm diameter) connecting distant cells. Astrocytes transfer mitochondria to stressed neurons via TNTs, driven by Miro1 motor protein regulation. See Tunneling Nanotubes
- Extracellular vesicles: Mitochondria packaged in large EVs and transferred between cells
- Direct cell contact: Gap junction-mediated transfer
| Method |
Route |
Advantages |
Limitations |
Status |
| Intra-arterial |
Endovascular catheter |
Targeted brain delivery, proven in stroke |
Invasive, acute window |
Phase 1 complete |
| Intranasal |
Nasal mucosa → CNS |
Non-invasive, bypasses BBB, repeatable |
Variable uptake |
Preclinical |
| Intravenous |
Systemic |
Simple administration |
Non-specific distribution |
Phase 1/2 |
| Direct injection |
Stereotactic |
Precise targeting |
Surgical risk, limited volume |
Preclinical |
| Encapsulation |
Various |
Extended viability, oral possible |
Manufacturing complexity |
Preclinical |
Intranasal mitochondrial transplantation bypasses the blood-brain barrier via the olfactory and trigeminal nerve pathways. In UQCRC1-mutation PD models, weekly intranasal administration of 1-2 × 10⁸ mitochondrial particles showed:
- Significant improvement in rotarod and pole test performance
- Dopaminergic neuron survival >60% in substantia nigra (vs ~30% in untreated)
- Restoration of Complex I activity in damaged neurons
- Sustained benefit with repeated dosing (3x weekly)
- Erythrocyte-derived vesicles (RBC-encapsulation): High delivery efficiency demonstrated in mice and primates
- ZIF-8 bio-encapsulation: Metal-organic framework preserves mitochondrial bioactivity for extended periods
- pH-responsive enteric capsules: Oral administration strategy (preclinical stage)
- "Mitlets" (Mitrix Bio): Bioreactor-grown mitochondria encased in protective vesicles — age-reset mitochondria from young donor cells
A landmark study published in Cell (Yao et al., 2026) demonstrated that transplantation of encapsulated mitochondria significantly improved functional outcomes in neurodegeneration models :
- Mitochondria encapsulated in biodegradable polymer matrices showed extended viability (weeks vs. hours)
- Oral administration feasible — mitochondria reached CNS via gut-brain axis
- Functional improvement in motor tests (rotarod, pole test) comparable to direct injection
- Reduced immune response vs. free mitochondria
This represents a major advance toward practical clinical deployment.
| Trial |
NCT ID |
Phase |
Indication |
Design |
Status |
| Autologous Mito Transplant for Stroke |
NCT04998357 |
Phase 1 |
Acute ischemic stroke |
20 patients, autologous muscle mito via catheter during thrombectomy |
Completed — safe, no SAEs |
| Taiwan Mito Transplant for PD |
NCT05094011 |
Phase 1 |
Parkinson's disease |
9 patients, ages 45-70, autologous mito via IV + intranasal |
Recruiting (as of 2025) |
| Paean Biotech IV Mito |
NCT04976140 |
Phase 1/2 |
Polymyositis/dermatomyositis |
18 adults, UC-MSC derived mito, IV |
Recruiting |
| Minovia MNV-201 |
NCT06017869 |
Phase 1/2 |
Pearson syndrome |
Mitochondrial augmentation technology |
Active |
| Boston Children's Hospital |
NCT02851758 |
Phase 1 |
Pediatric cardiac (ECMO) |
Autologous skeletal muscle mito → heart |
Completed |
Dr. Melanie Walker's group at the University of Washington completed the first-in-human brain mitochondrial transplantation in acute ischemic stroke patients. Mitochondria were isolated from patient muscle tissue adjacent to the surgical site and infused into the cerebral artery via microcatheter during endovascular reperfusion. Published in Journal of Cerebral Blood Flow & Metabolism (2024):
- No serious adverse events
- Safety profile comparable to matched controls
- Feasibility confirmed: mitochondria isolated and transplanted within acute treatment window
- Demonstrated clinical translatability of the approach
- MPTP and 6-OHDA models: Mitochondrial transplantation restored motor function (rotarod, pole test, locomotor activity), increased ETC Complex I activity, reduced ROS, and prevented dopaminergic neuron apoptosis
- Astrocytic transfer: Astrocyte-derived mitochondria transferred via TNTs protect dopaminergic neurons in co-culture models
- Intranasal route: Weekly intranasal delivery showed sustained neuroprotection in UQCRC1-mutation PD models (2024)
- MJFF-funded research: Michael J. Fox Foundation is funding "Surviving on Borrowed Energy" — investigating mitochondrial transfer as a PD therapeutic
- Aβ-treated neuronal cultures: astrocyte-derived mitochondria restored synaptic function
- Cognitive performance improvements in AD mouse models
- TNT-mediated mitochondrial transfer observed between astrocytes and neurons in response to Aβ stress
- Liver-derived mitochondria transplanted into PCKO mice with cerebellar ataxia improved mitochondrial function, reduced mitophagy, and delayed Purkinje cell apoptosis
- Symptom relief sustained for up to 3 weeks
- Published in Nature Communications (2025)
Mitochondrial transplantation is particularly relevant to CBS/PSP because tau pathology directly disrupts mitochondrial function:
- Tau-mitochondria binding: Hyperphosphorylated tau (PHF-1) localizes to synaptic mitochondria and directly binds ATP synthase, mitochondrial creatine kinase, and Drp1
- Impaired transport: Abnormal tau traps kinesin motor proteins, impairing axonal mitochondrial transport
- Excessive fission: Tau-Drp1 interaction causes excessive mitochondrial fragmentation
- Mitophagy dysfunction: Tau inhibits parkin translocation, disrupting mitochondrial quality control
- Complex I deficiency: PSP brains show Complex I inhibition similar to rotenone/MPTP models — the very mechanism that mitochondrial transplantation addresses
- Vicious cycle: Mitochondrial ROS elevation drives further tau phosphorylation and aggregation
Rationale for CBS/PSP: Even if tau pathology is the primary driver, restoring mitochondrial function could break the tau→mitochondrial damage→ROS→more tau phosphorylation cycle, potentially slowing disease progression.
¶ Key Companies and Institutions
| Entity |
Technology |
Focus |
Stage |
| Cellvie (Zurich) |
Off-the-shelf mito from cell lines |
Organ transplant → neuro |
Pre-Phase 1 |
| Mitrix Bio (Silicon Valley) |
"Mitlets" — bioreactor-grown, age-reset mito |
Aging reversal, neuro |
Safety trial planned 2025 |
| Paean Biotechnology |
UC-MSC derived mito, IV delivery |
Autoimmune → neuro |
Phase 1/2 |
| Minovia Therapeutics |
MNV-201 mito augmentation |
Rare mitochondrial diseases |
Phase 1/2 |
| University of Washington |
Autologous mito, endovascular |
Stroke → neurodegeneration |
Phase 1 complete |
| Taiwan Mito Applied Tech |
Autologous mito for PD |
Parkinson's disease |
Recruiting |
| Approach |
Mechanism |
Evidence Level |
Status |
Cost |
| CoQ10 |
Electron carrier, supports Complex I/III |
Phase 3 (NICE trial) |
Approved/supplement |
$ |
| NAD+ precursors (NMN/NR) |
Restore NAD+ → sirtuins/PGC-1α |
Phase 2 |
Research/supplement |
$$ |
| Urolithin A |
Mitophagy induction via mitophagy receptor modulation |
Phase 2 |
Approved/supplement |
$$$ |
| Mitochondrial transplantation |
Direct replacement of dysfunctional mitochondria |
Phase 1 |
Experimental |
$$$$ |
- CoQ10/NAD+ precursors: Best for early intervention, broad mitochondrial support, widely available
- Urolithin A: Best for enhancing mitophagy clearance of damaged mitochondria
- Mitochondrial transplantation: Consider when severe Complex I deficiency, failed conventional approaches, enrolled in trial
Mitochondrial transplantation could potentially work synergistically with:
- CoQ10: Enhanced electron transport chain support
- NAD+ precursors: Better integration and energy metabolism
- Exercise/modal: Increased mitochondrial biogenesis signals
¶ Challenges and Limitations
- Delivery to deep brain structures: CNS penetration remains the key challenge; intranasal route most promising but variable
- Mitochondrial viability: Isolated mitochondria lose function within hours without preservation (cyclosporin A preloading helps)
- Scale-up: Manufacturing sufficient quantities of viable mitochondria for repeated dosing
- Immune response: Allogeneic mitochondria may trigger innate immune activation via mtDNA (TLR9) and cardiolipin recognition
- Integration permanence: Transplanted mitochondria may not replicate; repeated dosing likely necessary
- mtDNA heteroplasmy: Mixing donor and recipient mtDNA genomes — long-term consequences unknown